Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SIGA Technologies Inc SIGA

Healthcare
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.


NDAQ:SIGA - Post by User

SIGA Technologies Inc
Bullboard Posts
User Avatar Image
(4)
•••
Post by AviseAnalyticson May 26, 2022 7:53am
192 Views
Post# 34708432

SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!

SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!
 
$SIGA
 
Siga Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company scored an FDA approval for its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). Given the rise of Monkeypox cases around the globe, can the Company leverage its expertise to make the most of the emerging opportunity?
 
https://www.aviseanalytics.com/sigas-smallpox-win-is-no-monkey-business/
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities